Navigation Links
OHSU Cancer Institute researchers find connection between protein, prognosis in breast cancer
Date:4/13/2008

PORTLAND, Ore. Oregon Health & Science University Cancer Institute researchers have found that a tumor protein present in an aggressive form of breast cancer is related to a poor prognosis.

The presence of the protein, called growth factor receptor-bound protein-7, often referred to as GRB-7, in breast cancer tumors, is strongly related to the growth and spread of the cancer, according to principal investigator Shiuh-Wen Luoh, M.D., Ph.D., assistant professor of medicine (hematology/medical oncology) in the OHSU School of Medicine.

The research will be presented Sunday, April 13, at 1 p.m. at the annual American Association for Cancer Research meeting in San Diego.

The GRB-7 protein previously has been shown to be important to cell communication in the spread of cancer. The GRB-7 gene is located close to the HER-2/Neu gene that regulates breast cancer growth. The OHSU Cancer Institute researchers discovered that the levels of GRB-7 protein are often heightened at the same time that HER-2/Neu levels are high. Also, not infrequently, they found breast tumors that overexpressed one but not the other protein. Overexpression means that there is an abundant presence of the protein.

It is surprising that we found discordance in the overexpression of these genes because they are so close together, Luoh said.

Researchers analyzed 563 primary breast cancer specimens. The samples were collected during a 20 year period for the OHSU Cancer Institute Breast Tumor and Clinical Data Repository.

The OHSU study shows that one in six breast tumors have high GRB-7 protein. These tumors have more aggressive, fast-growing and fast-spreading characteristics. HER-2/Neu positive tumors do not show these same features.

We think that identifying the individual contribution of the GRB-7 and its interaction with HER-2/ Neu gene may eventually help physicians better predict the clinical course of breast cancer in their patients. Also, new treatments might be designed to interfere with the actions of GRB-7 that can stop the growth and spread of a portion of breast cancer tumors, Luoh said.

Researchers have known that not all HER-2/Neu positive breast cancers shrink or slow their growth when treated with Trastuzumab or Lapatinib, targeted therapies against HER-2/Neu. The researchers speculate that GRB-7 might influence a tumors response to treatment. These findings are preliminary but could eventually lead to a clinical test for GRB-7 and better treatment for patients with GRB-7 positive breast tumors, Luoh explained.


'/>"/>

Contact: Christine Decker
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Drinking May Raise Breast Cancer Risk
2. Biomarker May Predict Response to Cancer Therapy
3. Breast Cancer Vaccine Works Against Deadlier Form of Disease
4. Karmanos Researchers Report Enhanced Chemosensitivity of Pancreatic Cancer Cells by Black Seed Component
5. Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer
6. Susan G. Komen for the Cure(R) Calls on Policymakers to Address Unfairness in Breast Cancer Incidence and Mortality
7. Radiation beneficial for older breast cancer patients
8. Cancer Drug Trials Often Halted Early
9. Mammography plus sonography can help rule out breast cancer in patients with palpable lesions
10. Newly diagnosed breast cancer patients benefit from use of USFNA of lymph nodes
11. New technique in treating patients with liver cancer proves effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will ... of Music Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention ... long been the gold standard for high-definition, in-ear earphones. This classic earphone has ...
(Date:1/17/2017)... ... 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting provider ... in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted that ... , Produced by Zeltiq, CoolSculpting is approved by the Food and Drug Administration ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons ... to primary eye care practitioners on the latest breakthroughs in the prevention, diagnosis ... Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive ...
(Date:1/17/2017)... ... 17, 2017 , ... Neil H. Greco Insurance Agency, a northern New Jersey ... region, is launching a charity drive to raise awareness of heart disease and promote ... in America, and is responsible for 1 in every 4 deaths at the national ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley ... double blind clinical study for its dental gel that shows significant reduction in plaque ... toothpaste containing triclosan. The study was conducted at the Beckman Laser Institute at UC ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Research Future published a Half Cooked Research Report on Endoscopy Devices ... 33.6 million during the period 2016 to 2022 from USD 28.7 ... ... examined as a swiftly growing market and expected to grow at ... in various regions.  The increasing growth in endoscopy procedures is influencing ...
(Date:1/17/2017)... KANSAS CITY, Mo. , Jan. ... (CHNC) has selected Velos and its flagship technology ... and multicenter initiatives. CHNC is a ... Neonatal Intensive Care Units at leading children,s hospitals ... consortium provides a benchmark of care and short-term ...
(Date:1/17/2017)...  Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is ... Inc. ("Anthera" or the "Company") (NASDAQ: ANTH ). ... the investigation by visiting the firm,s site: www.bgandg.com/anth .   ... its officers and/or directors have violated Sections 10(b) and 20(a) ... ...
Breaking Medicine Technology: